Yin Sun Selected Research

Androgen Antagonists (Antiandrogens)

11/2021	Suppressing BCL-XL increased the high dose androgens therapeutic effect to better induce the Enzalutamide-resistant prostate cancer autophagic cell death.
1/2021	Targeting androgen receptor (AR) with antiandrogen Enzalutamide increases prostate cancer cell invasion yet decreases bladder cancer cell invasion via differentially altering the AR/circRNA-ARC1/miR-125b-2-3p or miR-4736/PPARγ/MMP-9 signals.
3/2020	Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation.
12/2019	LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling.
1/2019	Targeting AR-Beclin 1 complex-modulated growth factor signaling increases the antiandrogen Enzalutamide sensitivity to better suppress the castration-resistant prostate cancer growth.
1/2019	Preclinical study using circular RNA 17 and micro RNA 181c-5p to suppress the enzalutamide-resistant prostate cancer progression.
1/2018	ASC-J9® suppresses prostate cancer cell invasion via altering the sumoylation-phosphorylation of STAT3.
11/2017	Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9® to Suppress Enzalutamide-resistant Prostate Cancer Progression.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yin Sun Research Topics

Disease

28	Neoplasms (Cancer) 12/2022 - 02/2009
25	Prostatic Neoplasms (Prostate Cancer) 03/2022 - 02/2009
17	Neoplasm Metastasis (Metastasis) 07/2022 - 06/2015
15	Renal Cell Carcinoma (Grawitz Tumor) 03/2022 - 10/2015
7	Hepatocellular Carcinoma (Hepatoma) 12/2020 - 10/2016
6	Carcinoma (Carcinomatosis) 04/2016 - 06/2012
5	Carcinogenesis 12/2022 - 02/2009
4	Inflammation (Inflammations) 01/2022 - 11/2010
4	Urinary Bladder Neoplasms (Bladder Cancer) 01/2021 - 01/2018
3	Adenocarcinoma 04/2016 - 11/2011
2	Mycoses (Diseases, Fungus) 12/2021 - 12/2019
2	Liver Neoplasms (Liver Cancer) 12/2020 - 01/2016
2	Hypoxia (Hypoxemia) 01/2019 - 10/2017
1	Neuroinflammatory Diseases 12/2022
1	Breast Neoplasms (Breast Cancer) 08/2022
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 07/2022
1	Fetal Weight 06/2022
1	Pregnancy Complications 06/2022
1	Invasive Fungal Infections 04/2022
1	Communicable Diseases (Infectious Diseases) 04/2022
1	Non-alcoholic Fatty Liver Disease 01/2022
1	Candidiasis (Moniliasis) 01/2022
1	Type 2 Diabetes Mellitus (MODY) 01/2022
1	Edema (Dropsy) 01/2022
1	Osteoarthritis 01/2022
1	Pain (Aches) 01/2022
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2022
1	Cholangiocarcinoma 12/2021
1	Overweight 08/2021
1	Urologic Neoplasms (Urological Cancer) 01/2021
1	Stroke (Strokes) 01/2020

Drug/Important Bio-Agent (IBA)

28	Androgen Receptors (Androgen Receptor)IBA 01/2021 - 02/2009
13	enzalutamideIBA 03/2022 - 01/2016
12	AndrogensIBA 03/2022 - 02/2009
9	MicroRNAs (MicroRNA)IBA 03/2022 - 10/2016
8	Androgen Antagonists (Antiandrogens)IBA 11/2021 - 11/2017
7	Circular RNAIBA 03/2022 - 11/2017
5	Phosphotransferases (Kinase)IBA 12/2022 - 11/2021
5	Biological ProductsIBA 08/2022 - 06/2015
4	Pharmaceutical PreparationsIBA 12/2022 - 12/2019
4	Therapeutic UsesIBA 06/2022 - 06/2012
4	Estrogen ReceptorsIBA 03/2022 - 01/2018
4	Proteins (Proteins, Gene)FDA Link 01/2021 - 05/2011
4	RNA (Ribonucleic Acid)IBA 01/2021 - 06/2015
4	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 01/2020 - 06/2015
4	Sorafenib (BAY 43-9006)FDA Link 01/2019 - 10/2016
3	Biomarkers (Surrogate Marker)IBA 03/2021 - 01/2015
3	Long Noncoding RNAIBA 01/2021 - 01/2017
2	Protein Kinases (Protein Kinase)IBA 08/2022 - 07/2022
2	Sunitinib (Sutent)FDA Link 03/2022 - 01/2020
2	TropomyosinIBA 02/2022 - 11/2021
2	AzolesIBA 01/2022 - 12/2019
2	6-methyladenineIBA 12/2021 - 01/2021
2	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 12/2021 - 01/2020
2	CateninsIBA 12/2020 - 01/2017
2	Docetaxel (Taxotere)FDA Link 09/2020 - 01/2020
2	Small Interfering RNA (siRNA)IBA 01/2018 - 11/2017
2	Estrogen Receptor betaIBA 01/2018 - 01/2018
2	EnzymesIBA 11/2017 - 04/2016
2	Oncogene Proteins (Oncogene Protein)IBA 09/2015 - 05/2011
2	Everolimus FDA Link 10/2012 - 06/2012
1	larotrectinibIBA 08/2022
1	pyrimidineIBA 08/2022
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 08/2022
1	Proteolysis Targeting ChimeraIBA 07/2022
1	Focal Adhesion Protein-Tyrosine KinasesIBA 07/2022
1	tyrosine receptor (receptor, tyrosine)IBA 07/2022
1	snake venom protein C activatorIBA 07/2022
1	Anti-Bacterial Agents (Antibiotics)IBA 06/2022
1	Antifungal AgentsIBA 04/2022
1	Lysine (L-Lysine)FDA Link 02/2022
1	Histone DemethylasesIBA 02/2022
1	CarrageenanIBA 01/2022
1	Formaldehyde (Formol)FDA Link 01/2022
1	Serotonin (5 Hydroxytryptamine)IBA 01/2022
1	Substance PIBA 01/2022
1	Xylenes (Xylene)IBA 01/2022
1	Dinoprostone (PGE2)FDA Link 01/2022
1	Interleukin-6 (Interleukin 6)IBA 01/2022
1	NeuregulinsIBA 01/2022
1	Collagen Type II (Type II Collagen)IBA 01/2022
1	ChromatinIBA 03/2021
1	ubiquitin-Nalpha-protein hydrolaseIBA 03/2021
1	Matrix Metalloproteinases (MMPs)IBA 01/2021
1	Histones (Histone)IBA 01/2021
1	N-methyladenosineIBA 01/2021
1	3' Untranslated Regions (3' UTR)IBA 12/2020
1	Messenger RNA (mRNA)IBA 12/2020
1	Oxygen (Dioxygen)IBA 10/2020
1	navitoclaxIBA 03/2020
1	Estradiol (Delestrogen)FDA LinkGeneric 01/2020
1	LigandsIBA 01/2020
1	Bexarotene (LGD1069)FDA Link 01/2020

Therapy/Procedure

29	Therapeutics 11/2021 - 02/2009
12	Castration 03/2022 - 06/2012
2	Drug Therapy (Chemotherapy) 09/2020 - 10/2016
1	Oral Administration 08/2022
1	Traditional Medicine (Folk Remedies) 01/2022
1	Cesarean Section (Caesarean Section) 08/2021
1	Immunotherapy 01/2021